Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

38 results
Display

A Case Report of Multiple Capillary Hemangioma in a Chronic Myeloid Leukemia Patient Taking Tyrosine Kinase Inhibitors

Byun HJ, Jang D, Lee J, Oh SJ, Lim Y, Park JH, Lee JH, Lee DY

A capillary hemangioma is a vascular tumor with small capillary sized vascular channel. Multiple capillary hemangioma in relation with drugs have been rarely reported. Here in, we report a case...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey

Uhm J, Kim KH, Lee H, Kim H, Cassandra S, Joo I, Jung CW

Background: The global TARGET survey examined real-world management of chronic myeloid leukemia (CML) compared with international guideline recommendations. This report focused on the responses of physicians from South Korea compared...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells

Na YJ, Yu ES, Kim DS, Lee DH, Oh SC, Choi CW

Background/Aims: Nilotinib is used for treating patients with imatinib-sensitive or -resistant chronic myeloid leukemia (CML); however, nilotinib-resistant cases have been observed in recent years. In addition, a considerable number of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

Gemelli M, Elli EM, Elena C, Iurlo A, Intermesoli T, Maffioli M, Pungolino E, Carraro MC, D’Adda M, Lunghi F, Anghileri M, Polverelli N, Rossi M, Bacciocchi M, Bono E, Bucelli C, Passamonti F, Antolini L, Gambacorti-Passerini C

Background Generic formulations of imatinib mesylate have been introduced in Western Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results on the safety and efficacy of generic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Emergence of Monosomy 7 in Philadelphia-Negative Cells during MDS Development and not CML Diagnosis Proved by Serial Droplet Digital PCR

Park S, Mun YC, Seong CM, Huh J

Emergence of new clonal chromosomal abnormality (CCA) has been reported in Philadelphia-negative cells in patients with chronic myeloid leukemia (CML) undergoing the tyrosine kinase inhibitor (TKI) treatment. However, the time...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay

Chung HJ, Hur M, Yoon S, Hwang K, Lim HS, Kim H, Moon HW, Yun YM

Accurate detection of BCR-ABL fusion transcripts at and below molecular response (MR) 4 (0.01% International Scale [IS]) is required for disease monitoring in patients with chronic myeloid leukemia (CML). We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy

Bedewy AM, Elmaghraby SM, Kandil NS

BACKGROUND: ATP-binding cassette transporters are important in the mechanism of multidrug resistance. ABCB1 displays a high affinity for imatinib. BMI1 is a polycomb group protein thought to be overexpressed in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dasatinib (Sprycel®)-Associated Acneiform Eruption Improved by Dose Reduction due to Pleural Effusion in a Patient with Chronic Myeloid Leukemia

Lim JH, Woo Y, Kim M, Park HJ

  • KMID: 2436860
  • Korean J Dermatol.
  • 2018 Aug;56(7):472-474.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Additional cytogenetic aberrations in chronic myeloid leukemia: a single-center experience in the Middle East

Safaei A, Monabati A, Safavi M, Atashabparvar A, Hosseini M

BACKGROUND: Additional cytogenetic aberrations are associated with disease progression in chronic myeloid leukemia (CML). This study was conducted to determine the type and frequency of these aberrations and their relationship...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21

Zhou X, Yuan P, Liu Q, Liu Z

Imatinib resistance has become a major clinical problem for chronic myeloid leukemia. The aim of the present study was to investigate the involvement of MEG3, a lncRNA, in imatinib resistance...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia

Dasgupta S, Ray UK, Mitra AG, Bhattacharyya DM, Mukhopadhyay A, Das P, Gangopadhyay S, Roy S, Mukhopadhyay S

BACKGROUND: Philadelphia chromosome, a hallmark of chronic myeloid leukemia (CML), plays a key role in disease pathogenesis. It reflects a balanced reciprocal translocation between long arms of chromosomes 9 and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach

Keramatinia A, Ahadi A, Akbari ME, Mohseny M, Jarahi AM, Mehrvar N, Mansouri N, Tabatabaei SAM, Movafagh A

Chronic myeloid leukemia (CML) is a hematological stem cell cancer driven by BCR-ABL1 fusion protein. We review the previous and recent evidence on the significance of CML in diagnostic and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Eruptive Melanocytic Nevi Induced by Radotinib

Lee WK, Jin H, You HS, Shim WH, Kim JM, Kim GW, Kim HS, Ko HC, Kim BS, Kim MB

  • KMID: 2401261
  • Korean J Dermatol.
  • 2017 Dec;55(10):706-708.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chronic Myeloid Leukemia Following Radioactive Iodine Treatment for Thyroid Cancer: Two Case Reports and a Literature Review

Park HY, Choi SE, Ryu YH, Change HS, Park CS, Lee KH, Kim YR

The incidence of thyroid cancer has increased rapidly worldwide, although most patients can survive for a long time without developing symptoms. While most thyroid cancers are treated with thyroidectomy alone,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells

Kim DS, Na YJ, Kang MH, Yoon SY, Choi CW

BACKGROUND/AIMS: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
ABCG2 C421A Polymorphism and Imatinib Response in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

Oh DH, Chun P

OBJECTIVE: To estimate the association between ABCG2 C421A polymorphism and response to imatinib in chronic myeloid leukemia. METHODS: A systematic review was conducted to evaluate the effect of ABCG2 C421A polymorphism...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chronic Myeloid Leukemia Relapsing as Isolated Extramedullary Disease Presenting as a Cardiac Mass

Byeon S, Kim HK, Moon JH, Moon SM, Park JE, Park S, Jung CW

Allogeneic hematopoietic stem cell transplantation is the only option for chemotherapy-refractory chronic myeloid leukemia (CML). Extramedullary relapse after transplantation is rare and usually accompanies marrow relapse. Generally, the prognosis of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Chronic Myeloid Leukemia with Multiple Chloromas Treated Successfully with Dasatinib

Jang WY, Choi SM, Park MS, Ahn BC, Heo MH, Kim JY, Kwon KY, Do YR

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of the primitive hematopoietic stem cells. CML is characterized by the overproduction of myeloid cells, which results in marked splenomegaly and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Successful Transcatheter Embolization of Spontaneous Splenic Rupture in a Patient with Chronic Myeloid Leukemia

Moon JY, Kim JM, Kwon KC, Shin BS, Ohm JY, Jo DY, Song IC

We report a rare case of a patient who presented with pathological splenic rupture as the initial manifestation of chronic myeloid leukemia (CML) and was treated successfully by transcatheter arterial...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia

Hong JH, Lee SE, Choi SY, Kim SH, Jang EJ, Bang JH, Park JE, Jeon HR, Oh YJ, Yi JE, Jung HO, Youn HJ, Kim DW

We describe two cases of pulmonary arterial hypertension (PAH) that occurred under dasatinib treatment and were resolved after dasatinib discontinuation. Two patients with chronic phase chronic myeloid leukemia (CML) were...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr